Male Fertility & Sperm Health: Evaluation, Causes, and Treatment

PhallusMD — Male Fertility

Male Fertility & Sperm Health: Evaluation, Causes, and Treatment

Male factor infertility accounts for approximately 50% of all infertility cases when both partners are considered. The semen analysis remains the cornerstone of evaluation, but sperm quality is a window into systemic male health — testicular function, hormonal status, genetics, and lifestyle all leave a measurable signature in the ejaculate.

~50%
of infertility cases involve a male factor when both partners are assessed
15%
of men have no identifiable cause after full workup (idiopathic infertility)
72 days
full spermatogenesis cycle; interventions take 3 months to show improvement
Most treatable causes: varicocele, hypogonadism, infections, obstruction, lifestyle factors
ART (IUI/IVF/ICSI) can overcome severe sperm defects when treatment fails

The Semen Analysis: What the Numbers Mean

The 2021 WHO reference values (5th percentile of fertile men) define the lower bounds of normal. A result below these values is not diagnostic of infertility — it describes reduced probability and guides workup, not outcome.

Parameter WHO 2021 Lower Reference Clinical significance if below
Volume 1.4 mL Low volume: ejaculatory duct obstruction, retrograde ejaculation, hypogonadism, collection error
Sperm concentration 16 million/mL Oligozoospermia: varicocele, hypogonadism, cryptorchidism, genetic cause
Total sperm count 39 million/ejaculate Low total count compounds concentration concerns
Total motility (PR+NP) 42% Asthenozoospermia: varicocele, oxidative stress, infection, sperm antibodies
Progressive motility (PR) 30% Key for natural conception and IUI
Morphology (Kruger strict) 4% Teratozoospermia: often idiopathic; impacts fertilization rate
Vitality 54% live Low vitality with low motility suggests structural defect (e.g., Kartagener syndrome)

Terminology: Oligospermia = low count; asthenospermia = low motility; teratospermia = abnormal morphology; azoospermia = no sperm in ejaculate (obstructive vs. non-obstructive). These may occur in combination (OAT syndrome = oligoasthenoteratozoospermia).

Causes of Male Infertility

Pretesticular (hormonal / endocrine)

  • Hypogonadotropic hypogonadism — low LH/FSH → low testosterone and low sperm production; causes include Kallmann syndrome, pituitary adenoma, exogenous testosterone/anabolic steroid use (the most common reversible cause in young men)
  • Hyperprolactinemia — suppresses GnRH → low LH/FSH → low T and impaired spermatogenesis
  • Thyroid disorders — both hypo- and hyperthyroidism impair spermatogenesis

Testicular (intrinsic)

  • Varicocele — most common surgically correctable cause; dilated pampiniform plexus raises scrotal temperature, impairs spermatogenesis (see Varicocele page)
  • Cryptorchidism — undescended testis; even after orchiopexy, fertility may be reduced; bilateral cryptorchidism carries the highest risk
  • Genetic causes — Y chromosome microdeletions (AZFa/b/c regions), Klinefelter syndrome (47,XXY); karyotype and Y-deletion testing indicated when sperm concentration <5 million/mL
  • Testicular torsion or trauma — ischemic injury; antisperm antibodies may develop post-torsion
  • Orchitis — mumps orchitis (post-pubertal) causes atrophy and azoospermia in ~30%; STI-related orchitis (gonorrhea, chlamydia)
  • Idiopathic — no identifiable cause found after full workup; ~15% of male infertility

Post-testicular (obstruction / ejaculatory)

  • Obstructive azoospermia — sperm production is normal but egress is blocked: epididymal obstruction (post-infection, congenital), vas deferens absence (CBAVD — linked to CF mutations), ejaculatory duct obstruction (cysts, infection), vasectomy
  • Retrograde ejaculation / anejaculation — see dedicated pages

Lifestyle and environmental factors

  • Exogenous testosterone / anabolic steroids — suppresses HPG axis → azoospermia; most cases reverse after cessation (3–18 months)
  • Heat exposure (laptop on lap, hot tubs, tight underwear) — mild, reversible
  • Smoking — reduces concentration, motility, and morphology
  • Alcohol — moderate evidence; heavy use impairs testosterone and spermatogenesis
  • Obesity — increases scrotal temperature, estrogen, reduces testosterone
  • Radiation and chemotherapy — variable; sperm banking before treatment is strongly recommended

Workup

Initial evaluation

  • Two semen analyses, 2–7 days abstinence, ≥2 weeks apart
  • Reproductive hormones: FSH, LH, total testosterone, prolactin, estradiol
  • Testicular exam: volume (Prader orchidometer or ultrasound), consistency, epididymis, vas deferens, varicocele

When to extend the workup

  • Azoospermia or severe oligospermia (<5M/mL): karyotype, Y-chromosome microdeletion, CFTR mutation testing
  • Low semen volume with normal concentration: post-ejaculatory urinalysis (rule out retrograde ejaculation), transrectal ultrasound (ejaculatory duct obstruction)
  • Elevated FSH with azoospermia: likely non-obstructive; testicular biopsy or mTESE may be indicated
  • Scrotal ultrasound: varicocele confirmation, testicular parenchyma, epididymal dilation
  • Sperm DNA fragmentation: when recurrent pregnancy loss or repeated IVF failure despite adequate sperm count

Treatment

Treat reversible causes

  • Varicocele repair: improves semen parameters in ~60–70%; most benefit in clinical (palpable) varicocele with oligospermia
  • Stop exogenous testosterone: HCG or clomiphene/enclomiphene to restore HPG axis (see HCG & Enclomiphene page)
  • Treat hypogonadotropic hypogonadism: HCG ± FSH supplementation; often restores spermatogenesis even from azoospermia
  • Treat infections: STIs, epididymitis; antibiotic therapy
  • Lifestyle modification: weight loss, smoking cessation, eliminating heat exposure, reducing alcohol

Empirical medical therapy (limited evidence)

For idiopathic oligospermia/OAT, the evidence base is thin but the following are used:

  • Clomiphene citrate / enclomiphene (25–50 mg/day) — raises LH/FSH, improves testosterone; mixed RCT evidence for sperm counts in idiopathic cases
  • Antioxidants (vitamin C, E, CoQ10, L-carnitine, zinc) — large RCTs (most recently MOXI trial 2020) have not shown consistent benefit; individual antioxidant or combination use remains common practice despite inconclusive evidence
  • FSH supplementation — recombinant FSH or hMG; used when FSH is at or below normal in idiopathic oligospermia; some positive RCT data

Surgical sperm retrieval + ART

When spermatogenesis occurs but sperm cannot be ejaculated (obstruction) or when sperm count is very low, sperm can be retrieved surgically:

  • PESA/TESA: percutaneous aspiration from epididymis or testis; used for obstructive azoospermia
  • mTESE (microdissection testicular sperm extraction): open surgery under microscopy to identify tubules producing sperm in non-obstructive azoospermia; sperm found in 40–60% of NOA men; combined with ICSI

Consult a Reproductive Urologist

Male infertility evaluation should be prompt and thorough — not an afterthought. Many causes are treatable, and the right evaluation changes the treatment plan for both partners.

PhallusMD is an informational resource and does not provide medical advice, diagnosis, or treatment. Speak with a reproductive urologist or reproductive endocrinologist for evaluation and management.

Key References

  1. WHO Laboratory Manual for the Examination and Processing of Human Semen, 6th ed. 2021. Geneva: WHO Press.
  2. Schlegel PN et al. Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline. J Urol. 2021;205(1):36–43.
  3. Majzoub A et al. Antioxidant therapy in idiopathic infertility: a systematic review and meta-analysis. Arab J Urol. 2018;16(1):149–159.
  4. Esteves SC et al. Microdissection testicular sperm extraction with intracytoplasmic sperm injection: a systematic review. Clinics. 2013;68(S1):79–87.
  5. Dohle GR et al. EAU Guidelines on Male Infertility. Eur Urol. 2012;62(2):324–332.